Ovarian cancer

Why we focus on ovarian cancer

There are around 7,500 new ovarian cancer cases in the UK every year and more than half of those diagnosed will die of the disease. There is no screening technique, and most patients (~60%) present with advanced disease because symptoms are not easy to recognise or distinguish from other, less serious conditions, often leading to late or mis‑diagnosis. Treatment involves aggressive surgery and platinum-based chemotherapy, and progress in the last 30 years has led to the overall five year survival rate doubling and more than 40% of women now live for at least five years. However, for the majority who present with advanced disease, more than 70% will die within five years of diagnosis. Therefore, there is a great need to develop new therapies for this disease, based upon greater understanding of its biology.

What we do
  • Our focus is on translational research, aimed at developing new treatments for women with ovarian cancer
  • We aim to understand the links between cancer and inflammation
  • We are investigating the impact of modulating the tumour-promoting cells and mediators of inflammation
  • Viral gene therapies are being developed
  • We are investigating the interaction of oncolytic viruses with the host immune system
  • We are exploring the relationship between cellular DNA damage repair and adenovirus biology, particularly homologous recombination
  • Novel agents are being tested in Phase I and II clinical trials.
Major Funders
  • Cancer Research UK
  • BBSRC
  • Medical Research Council
  • Ovarian Cancer Action
  • Wellbeing of Women
Key Publications